Education
About Us
Working with TipRanks
Follow Us
Boston Scientific (BSX)
NYSE:BSX
BSX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$66.80 - $107.17
Previous CloseN/A
Volume5.49M
Average Volume (3M)9.72M
Market Cap
$138.54B
Enterprise Value$144.04B
Total Cash (Recent Filing)$519.00M
Total Debt (Recent Filing)$5.92B
Price to Earnings (P/E)75.1
Beta0.85
Next Earnings
Apr 23, 2025EPS Estimate
0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.70
Shares Outstanding1,479,070,200
10 Day Avg. Volume12,844,961
30 Day Avg. Volume9,720,199
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.87
Price to Cash Flow (P/CF)25.50
P/FCF Ratio29.60
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit12.54
Enterprise Value/Ebitda37.29
Forecast
1Y Price Target
$120.65Price Target Upside18.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
---
Bulls Say, Bears Say
Bulls Say
EarningsBSX's revenue and EPS came in ahead of both analyst and consensus expectations, showcasing strong operational performance.
Financial GuidanceManagement raised its FY25 guidance ahead of consensus estimates, highlighting strong performance and growth potential.
Market PositionThe company has taken the #2 position in the worldwide EP market, driven by Farapulse and Watchman.
Bears Say
CompetitionBSX sees some headwind from low-cost competition in urology and endoscopy, particularly outside the US.
Tariff Impact$200M of tariff impacts is contemplated in the 2025 guidance, expected to begin impacting the company in the second half of the year.
---
Ownership Overview
0.18% Insiders
29.83% Mutual Funds
0.50% Other Institutional Investors
47.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BSX FAQ
What was Boston Scientific’s price range in the past 12 months?
Boston Scientific lowest stock price was $66.80 and its highest was $107.17 in the past 12 months.
What is Boston Scientific’s market cap?
Boston Scientific’s market cap is $138.54B.
When is Boston Scientific’s upcoming earnings report date?
Boston Scientific’s upcoming earnings report date is Apr 23, 2025 which is 3 days ago.
How were Boston Scientific’s earnings last quarter?
Boston Scientific released its earnings results on Apr 23, 2025. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.673 by $0.077.
Is Boston Scientific overvalued?
According to Wall Street analysts Boston Scientific’s price is currently Undervalued.
Does Boston Scientific pay dividends?
Boston Scientific does not currently pay dividends.
What is Boston Scientific’s EPS estimate?
Boston Scientific’s EPS estimate is 0.67.
How many shares outstanding does Boston Scientific have?
Boston Scientific has 1,479,070,200 shares outstanding.
What happened to Boston Scientific’s price movement after its last earnings report?
Boston Scientific reported an EPS of $0.75 in its last earnings report, beating expectations of $0.673. Following the earnings report the stock price went up 4.072%.
Which hedge fund is a major shareholder of Boston Scientific?
Currently, no hedge funds are holding shares in BSX
---
Boston Scientific Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$120.65 (18.40% Upside)
$120.65 (18.40% Upside)
Blogger Sentiment
Bullish
BSX Sentiment 78%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.06%
12-Months-Change
Fundamentals
Return on Equity
9.03%
Trailing 12-Months
Asset Growth
12.12%
Trailing 12-Months
Company Description
Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
---
BSX Company Deck
---
BSX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook with strong revenue and EPS growth exceeding expectations, particularly in the cardiology and electrophysiology segments. However, challenges such as significant tariff impacts, slower growth in certain segments, and foreign exchange headwinds were noted, adding some concerns to the otherwise strong performance.Read More>---
BSX Revenue Breakdown
64.22% Cardiovascular
35.79% MedSurg
---
BSX Stock 12 Month Forecast
Average Price Target
$120.65
▲(18.40% Upside)
Technical Analysis
Abbott Laboratories
―
Intuitive Surgical
―
Medtronic
―
Stryker
―
Zimmer Biomet Holdings
―
Best Analysts Covering BSX
1 Year
1 Year Success Rate
26/28 ratings generated profit
1 Year Average Return
+27.86%
reiterated a buy rating 4 days ago
Copying Shagun Singh Chadha's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +27.86% per trade.
---